The U.S. Food and Drug Administration on Tuesday declined to approve Nabriva Therapeutics Plc's antibiotic for complicated urinary tract infections (cUTI), even as the nation grapples with the growing problem of antibiotic resistance.
from Reuters: Health News https://reut.rs/2GMpDjh
via
IFTTT
0 comments:
Post a Comment